76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Achieve Life Sciences Inc
Closed
3.07 13.7
Overview
Share price change
24h
Min
2.68
Max
3.08
Income | 152K -12M |
|---|---|
EPS | -0.36 |
Employees | 25 |
EBITDA | -16K -12M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +458.61% upside |
Next Earnings | 12 Aug 2025 |
|---|
Market Cap | -22M 86M |
|---|---|
Previous open | -10.63 |
Previous close | 3.07 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Achieve Life Sciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Achieve Life Sciences Inc Forecast
Price Target
By TipRanks
458.61% upside
12 Months Forecast
Average 15.25 USD 458.61%
High 20 USD
Low 10 USD
Based on 4 Wall Street analysts offering 12 month price targets forAchieve Life Sciences Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
